CU Anschutz
Anschutz Health Sciences Building
1890 N Revere Ct
Suite 6202
Aurora, CO 80045
Q32 Bio & Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of bempikibart (formerly ADX-914) for Severe Alopecia Areata
Default sub title
minute read
by PR Newswire | September 13, 2023
